Last update Dec. 10, 2022
A Calcium channel blocker with spasmolytic activity on the intestine and antimuscarinic effects. It is used for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract. Oral administration.
At latest update no published data were found on excretion into breast milk.
Its pharmacokinetic data (moderately high molecular weight and high protein binding) make unlikely the passage into milk in significant amounts.
Its very low oral bioavailability hinders its passage into infant's plasma from ingested milk, except in preterm infants and immediate neonatal period, since they may exhibit an increased intestinal permeability.
Although antimuscarinics can decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM